Does the media prefer COGT or UTHR?

In the previous week, United Therapeutics had 17 more articles in the media than Cogent Biosciences. MarketBeat recorded 19 mentions for United Therapeutics and 2 mentions for Cogent Biosciences. United Therapeutics' average media sentiment score of 0.73 beat Cogent Biosciences' score of 0.27 indicating that United Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral United Therapeutics 12 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor GMAB or COGT?

In the previous week, Genmab A/S had 2 more articles in the media than Cogent Biosciences. MarketBeat recorded 4 mentions for Genmab A/S and 2 mentions for Cogent Biosciences. Genmab A/S's average media sentiment score of 0.65 beat Cogent Biosciences' score of 0.27 indicating that Genmab A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cogent Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to COGT or ASND?

In the previous week, Ascendis Pharma A/S had 5 more articles in the media than Cogent Biosciences. MarketBeat recorded 7 mentions for Ascendis Pharma A/S and 2 mentions for Cogent Biosciences. Ascendis Pharma A/S's average media sentiment score of 0.48 beat Cogent Biosciences' score of 0.27 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ascendis Pharma A/S 2 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to COGT or BBIO?

In the previous week, BridgeBio Pharma had 6 more articles in the media than Cogent Biosciences. MarketBeat recorded 8 mentions for BridgeBio Pharma and 2 mentions for Cogent Biosciences. BridgeBio Pharma's average media sentiment score of 0.53 beat Cogent Biosciences' score of 0.27 indicating that BridgeBio Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BridgeBio Pharma 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, SMMT or COGT?

Summit Therapeutics is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Summit Therapeutics N/A N/A -$1.08B -$1.12 N/A Cogent Biosciences N/A N/A -$328.94M -$2.16 N/A

Is SMMT or COGT more profitable?

Cogent Biosciences' return on equity of -84.47% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Summit Therapeutics N/A -168.94% -141.92% Cogent Biosciences N/A -84.47% -47.72%

Does the media refer more to SMMT or COGT?

In the previous week, Summit Therapeutics had 8 more articles in the media than Cogent Biosciences. MarketBeat recorded 10 mentions for Summit Therapeutics and 2 mentions for Cogent Biosciences. Summit Therapeutics' average media sentiment score of 0.32 beat Cogent Biosciences' score of 0.27 indicating that Summit Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Cogent Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Cogent Biosciences (COGT) Competitors

$30.96 -1.67 (-5.10%)

As of 12:57 PM Eastern

Compare

COGT vs. UTHR, GMAB, ASND, BBIO, and SMMT

Should you buy Cogent Biosciences stock or one of its competitors? Cogent Biosciences's main competitors and comparable companies include United Therapeutics (UTHR), Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), and Summit Therapeutics (SMMT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Cogent Biosciences compare to United Therapeutics?

Cogent Biosciences (NASDAQ:COGT) and United Therapeutics (NASDAQ:UTHR) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

United Therapeutics has a net margin of 41.56% compared to Cogent Biosciences' net margin of 0.00%. United Therapeutics' return on equity of 20.18% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-84.47%	-47.72%
United Therapeutics	41.56%	20.18%	17.98%

Cogent Biosciences currently has a consensus price target of $51.56, suggesting a potential upside of 66.07%. United Therapeutics has a consensus price target of $646.00, suggesting a potential upside of 31.67%. Given Cogent Biosciences' higher possible upside, analysts plainly believe Cogent Biosciences is more favorable than United Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85

In the previous week, United Therapeutics had 17 more articles in the media than Cogent Biosciences. MarketBeat recorded 19 mentions for United Therapeutics and 2 mentions for Cogent Biosciences. United Therapeutics' average media sentiment score of 0.73 beat Cogent Biosciences' score of 0.27 indicating that United Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
United Therapeutics	12 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

94.1% of United Therapeutics shares are held by institutional investors. 6.6% of Cogent Biosciences shares are held by company insiders. Comparatively, 8.6% of United Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Cogent Biosciences has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market.

United Therapeutics has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.16	N/A
United Therapeutics	$3.18B	6.61	$1.33B	$27.95	17.55

Summary

United Therapeutics beats Cogent Biosciences on 14 of the 16 factors compared between the two stocks.

How does Cogent Biosciences compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and Cogent Biosciences (NASDAQ:COGT) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation.

Genmab A/S presently has a consensus price target of $39.50, suggesting a potential upside of 13.59%. Cogent Biosciences has a consensus price target of $51.56, suggesting a potential upside of 66.07%. Given Cogent Biosciences' higher possible upside, analysts plainly believe Cogent Biosciences is more favorable than Genmab A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Genmab A/S had 2 more articles in the media than Cogent Biosciences. MarketBeat recorded 4 mentions for Genmab A/S and 2 mentions for Cogent Biosciences. Genmab A/S's average media sentiment score of 0.65 beat Cogent Biosciences' score of 0.27 indicating that Genmab A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cogent Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Genmab A/S has a net margin of 19.08% compared to Cogent Biosciences' net margin of 0.00%. Genmab A/S's return on equity of 14.89% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	19.08%	14.89%	7.73%
Cogent Biosciences	N/A	-84.47%	-47.72%

Genmab A/S has a beta of 0.84, meaning that its stock price is 16% less volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market.

7.1% of Genmab A/S shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by insiders. Comparatively, 6.6% of Cogent Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Genmab A/S has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	5.83	$963M	$1.27	27.38
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.16	N/A

Summary

Genmab A/S beats Cogent Biosciences on 13 of the 15 factors compared between the two stocks.

How does Cogent Biosciences compare to Ascendis Pharma A/S?

Cogent Biosciences (NASDAQ:COGT) and Ascendis Pharma A/S (NASDAQ:ASND) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

Ascendis Pharma A/S has a net margin of 70.99% compared to Cogent Biosciences' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 32.54% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-84.47%	-47.72%
Ascendis Pharma A/S	70.99%	32.54%	7.71%

Ascendis Pharma A/S has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.16	N/A
Ascendis Pharma A/S	$814.57M	17.50	-$258M	$12.89	17.73

Cogent Biosciences has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market.

Cogent Biosciences currently has a consensus target price of $51.56, indicating a potential upside of 66.07%. Ascendis Pharma A/S has a consensus target price of $310.75, indicating a potential upside of 36.00%. Given Cogent Biosciences' higher possible upside, analysts plainly believe Cogent Biosciences is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	3.00

In the previous week, Ascendis Pharma A/S had 5 more articles in the media than Cogent Biosciences. MarketBeat recorded 7 mentions for Ascendis Pharma A/S and 2 mentions for Cogent Biosciences. Ascendis Pharma A/S's average media sentiment score of 0.48 beat Cogent Biosciences' score of 0.27 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ascendis Pharma A/S	2 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Ascendis Pharma A/S beats Cogent Biosciences on 12 of the 13 factors compared between the two stocks.

How does Cogent Biosciences compare to BridgeBio Pharma?

Cogent Biosciences (NASDAQ:COGT) and BridgeBio Pharma (NASDAQ:BBIO) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, media sentiment and institutional ownership.

Cogent Biosciences has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -97.03%. BridgeBio Pharma's return on equity of 0.00% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-84.47%	-47.72%
BridgeBio Pharma	-97.03%	N/A	-61.19%

99.9% of BridgeBio Pharma shares are held by institutional investors. 6.6% of Cogent Biosciences shares are held by insiders. Comparatively, 14.2% of BridgeBio Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Cogent Biosciences has higher earnings, but lower revenue than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.16	N/A
BridgeBio Pharma	$502.08M	25.73	-$724.93M	-$3.57	N/A

In the previous week, BridgeBio Pharma had 6 more articles in the media than Cogent Biosciences. MarketBeat recorded 8 mentions for BridgeBio Pharma and 2 mentions for Cogent Biosciences. BridgeBio Pharma's average media sentiment score of 0.53 beat Cogent Biosciences' score of 0.27 indicating that BridgeBio Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BridgeBio Pharma	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cogent Biosciences currently has a consensus target price of $51.56, suggesting a potential upside of 66.07%. BridgeBio Pharma has a consensus target price of $102.61, suggesting a potential upside of 55.25%. Given Cogent Biosciences' higher probable upside, equities research analysts clearly believe Cogent Biosciences is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83

Cogent Biosciences has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market.

Summary

BridgeBio Pharma beats Cogent Biosciences on 9 of the 16 factors compared between the two stocks.

How does Cogent Biosciences compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and Cogent Biosciences (NASDAQ:COGT) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Summit Therapeutics is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.16	N/A

Summit Therapeutics has a beta of -1.24, meaning that its stock price is 224% less volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market.

Cogent Biosciences' return on equity of -84.47% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-168.94%	-141.92%
Cogent Biosciences	N/A	-84.47%	-47.72%

Summit Therapeutics currently has a consensus target price of $25.91, suggesting a potential upside of 58.42%. Cogent Biosciences has a consensus target price of $51.56, suggesting a potential upside of 66.07%. Given Cogent Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Cogent Biosciences is more favorable than Summit Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	1 Sell rating(s)	9 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.41
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Summit Therapeutics had 8 more articles in the media than Cogent Biosciences. MarketBeat recorded 10 mentions for Summit Therapeutics and 2 mentions for Cogent Biosciences. Summit Therapeutics' average media sentiment score of 0.32 beat Cogent Biosciences' score of 0.27 indicating that Summit Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cogent Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

4.6% of Summit Therapeutics shares are owned by institutional investors. 83.5% of Summit Therapeutics shares are owned by insiders. Comparatively, 6.6% of Cogent Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Cogent Biosciences beats Summit Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Cogent Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COGT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

COGT vs. The Competition

Export

Metric	Cogent Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.39B	$3.90B	$7.22B	$13.12B
Dividend Yield	N/A	3.64%	2.53%	12.99%
P/E Ratio	-14.37	14.36	274.48	25.76
Price / Sales	N/A	1,360.25	648.15	88.46
Price / Cash	N/A	109.50	76.31	52.02
Price / Book	8.08	15.25	10.44	6.32
Net Income	-$328.94M	-$22.82M	$3.49B	$359.84M
7 Day Performance	-4.60%	0.04%	0.94%	1.78%
1 Month Performance	-15.48%	-5.78%	-3.04%	-3.33%
1 Year Performance	139.91%	35.30%	16.50%	5.92%

Cogent Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
COGT Cogent Biosciences	2.0459 of 5 stars	$30.98 -5.1%	$51.56 +66.4%	+160.8%	$5.37B	N/A	N/A	258
UTHR United Therapeutics	4.3053 of 5 stars	$502.70 +1.1%	$646.00 +28.5%	+20.0%	$21.32B	$3.18B	17.99	1,400	Insider Trade
GMAB Genmab A/S	4.2723 of 5 stars	$32.65 +0.6%	$39.50 +21.0%	+23.1%	$20.25B	$4.13B	25.71	3,029
ASND Ascendis Pharma A/S	4.6445 of 5 stars	$264.92 +0.5%	$310.00 +17.0%	+21.0%	$16.44B	$814.57M	20.55	1,189
BBIO BridgeBio Pharma	3.3936 of 5 stars	$72.38 -0.1%	$102.61 +41.8%	+34.3%	$14.16B	$713.07M	N/A	839	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:COGT) was last updated on 9/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cogent Biosciences (COGT) Competitors

COGT vs. UTHR, GMAB, ASND, BBIO, and SMMT

How does Cogent Biosciences compare to United Therapeutics?

Summary

How does Cogent Biosciences compare to Genmab A/S?

Summary

How does Cogent Biosciences compare to Ascendis Pharma A/S?

Summary

How does Cogent Biosciences compare to BridgeBio Pharma?

Summary

How does Cogent Biosciences compare to Summit Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COGT vs. The Competition

Cogent Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cogent Biosciences (COGT) Competitors

COGT vs. UTHR, GMAB, ASND, BBIO, and SMMT

How does Cogent Biosciences compare to United Therapeutics?

Is COGT or UTHR more profitable?

Do analysts prefer COGT or UTHR?

Does the media prefer COGT or UTHR?

Do insiders & institutionals have more ownership in COGT or UTHR?

Which has more risk and volatility, COGT or UTHR?

Which has better valuation & earnings, COGT or UTHR?

Summary

How does Cogent Biosciences compare to Genmab A/S?

Do analysts prefer GMAB or COGT?

Does the media favor GMAB or COGT?

Is GMAB or COGT more profitable?

Which has more volatility and risk, GMAB or COGT?

Do institutionals and insiders have more ownership in GMAB or COGT?

Which has better valuation & earnings, GMAB or COGT?

Summary

How does Cogent Biosciences compare to Ascendis Pharma A/S?

Is COGT or ASND more profitable?

Which has stronger earnings and valuation, COGT or ASND?

Which has more volatility and risk, COGT or ASND?

Do analysts recommend COGT or ASND?

Does the media refer more to COGT or ASND?

Summary

How does Cogent Biosciences compare to BridgeBio Pharma?

Is COGT or BBIO more profitable?

Do institutionals and insiders hold more shares of COGT or BBIO?

Which has preferable valuation and earnings, COGT or BBIO?

Does the media refer more to COGT or BBIO?

Do analysts recommend COGT or BBIO?

Which has more volatility & risk, COGT or BBIO?

Summary

How does Cogent Biosciences compare to Summit Therapeutics?

Which has better earnings and valuation, SMMT or COGT?

Which has more volatility and risk, SMMT or COGT?

Is SMMT or COGT more profitable?

Do analysts recommend SMMT or COGT?

Does the media refer more to SMMT or COGT?

Do insiders & institutionals have more ownership in SMMT or COGT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COGT vs. The Competition

Cogent Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools